Yu-Hao Huang^1,#, Hao-Yeh Chen^2,#, Peng-Ju Chien¹, Chun-Yu Chen^2,3, Shao-Ti Li⁴, Hsueh-Te Lee⁵, Yueh-Chun Lee^4,6,*, Wen-Wei Chang^1,7,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.080978 - 16 June 2026

Abstract Backgrounds: Triple-negative breast cancer (TNBC) is highly aggressive, insensitive to radiotherapy, and exhibits increased cancer stem cell (CSC) properties, contributing to poor patient outcomes. B-cell lymphoma 2 (BCL2) associated transcription factor 1 (BCLAF1) is an oncogene in certain cancers, but its role in TNBC is unclear. This study investigated BCLAF1’s involvement in radioresistance and CSC activity in TNBC. Methods: BCLAF1 expression and clinical significance were analyzed using The Cancer Genome Atlas (TCGA) breast cancer dataset. Radioresistant MDA-MB-231 cells were used to examine BCLAF1’s function. Proto-oncogene SRC (SRC) overexpression, BCLAF1 knockdown, dasatinib treatment, and hypoxia inducible factor 1 subunit… More >

Irene Bernal-Florindo^1,2, Jose Angel Raposo-Puglia^2,3, Felix A. Ruiz^2,4, Jose Perez-Requena^2,5, Cristian Benavides-de la Fuente^2,5, Javier Galan^2,6, Maria Jose Berruezo-Salazar^2,7, Marcial Garcia-Rojo^1,2, Cecilia Fernandez-Ponce^2,4,*, Antonio Santisteban-Espejo^2,8

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.079403 - 16 June 2026

Abstract Classic Hodgkin lymphoma (CHL) constitutes a B-cell malignant lymphoid neoplasm derived from the germinal center. Despite current treatment protocols based on chemotherapy, radiotherapy, anti-cluster of differentiation (CD) 30 antibody-drug conjugates, immunotherapy, and hematopoietic stem cell transplantation (HSCT), between 10% and 20% of CHL patients fail to achieve a complete response. The reasons underlying this lack of treatment sensitivity remain unclear. Traditionally, clinical and analytical variables have constituted the cornerstone of CHL prognostic model development. However, in recent years, the distribution and spatial relationships of cancer and immune cells within the CHL tumor microenvironment (TME) have… More >

Zhihao Yin^1,2,3,#, Xi Zhen^4,#, Haonan Li^1,2,3,#, Haiqiang Duan^1,2,3,#, Xiaowei Hu^5,#, Tianxi Yu¹, Qing Shi¹, Ziyi Liu¹, Yaowei Li¹, Peng Zhang¹, Peng Dai¹, Meihui Zhao⁶, Ziqi Wang^1,2,3,7,*, Changfu Li^2,*, Di Wang^1,*, Zhichao Tong^1,3,5,8,9,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.077808 - 16 June 2026

Abstract Backgrounds: Tertiary lymphoid structures (TLSs) are increasingly recognized as modulators of anti-tumor immunity, yet their clinical relevance in bladder cancer remains incompletely understood, partly owing to heterogeneity in their maturation states. Here, we demonstrate that germinal center (GC)–like TLS maturity, rather than TLS presence alone, is closely associated with immune activation and therapeutic response to Programmed Death-Ligand 1 (PD-L1) blockade in bladder cancer. The objective of this study was to systematically investigate the clinical significance, biological function, and therapeutic potential of tertiary lymphoid structure (TLS) maturation in bladder cancer. Specifically, we aimed to determine whether GC-like… More >

Christoph Rehbach¹, Patrick A. H. Ehm^2,*

BIOCELL, Vol.50, No.5, 2026, DOI:10.32604/biocell.2026.075170 - 13 May 2026

Abstract Despite improved overall prognosis, the treatment of high-risk acute lymphoblastic leukemia (ALL) remains challenging due to the toxicity of intensive polychemotherapy and the limited efficacy of antibody-targeted therapies beyond cluster of differentiation 20 and 22 (CD20 and CD22). ALL is driven not only by genetic alterations but also by profound epigenetic dysregulation, including promoter hypermethylation that also silences surface receptor genes. This epigenetic repression can reduce the efficacy of targeted immunotherapies and contribute to relapse. Epigenetic reprogramming with DNA demethylating agents (e.g., decitabine) has the potential to restore the expression of key B cell receptors… More >

George Liatsos^*, Kalliopi Zioutou, Konstantinos Avramidis, Konstantinos Vamvakaris, Maria Potamiti-Komi, Dimitrios Vassilopoulos

Canadian Journal of Urology, Vol.33, No.2, pp. 349-360, 2026, DOI:10.32604/cju.2026.072711 - 20 April 2026

Abstract Objectives: Bladder cancer (BC) is a prevalent malignancy with evolving treatment strategies and an increasingly aging patient population, resulting in a growing and complex burden of hospitalizations that extends beyond urological care and remains insufficiently characterized in real-world Internal Medicine settings. This study aimed to analyze the clinical data and outcomes for patients with BC admitted to the medicine ward. Additionally, this research presents three cases of fever of unknown origin, which all exhibited identical clinical and laboratory findings but ultimately resulted in different disease diagnoses. Methods: This retrospective case-series study included all adult patients… More >

Jiawen Chen^1,#, Zelin Liu^1,#, Keke Huang¹, Jinlan Li¹, Yajie Zhang¹, Dandan Chen¹, Yanjie Ruan², Ying Pan¹, Furun An¹, Yang Wan^1,*, Jiyu Wang^1,3,*, Qianshan Tao^1,*

European Cytokine Network, Vol.37, No.1, pp. 25-39, 2026, DOI:10.32604/ecn.2026.077875 - 13 April 2026

Abstract Objectives: B-cell lymphoma exhibits significant clinical heterogeneity, necessitating improved biomarkers for risk stratification. C-C chemokine receptor 7 (CCR7) and trimethylation of histone H3 lysine 9 (H3K9me3) are implicated in cellular senescence and tumor invasion. While the clinical significance of their co-expression in lymphomagenesis remains unclear. This study aims to define the expression profiles of CCR7 and H3K9me3 in B-cell lymphoma, explore their correlation with aggressive clinical indicators, and evaluate their combined prognostic value. Methods: The expression of CCR7 and H3K9me3 in tumor tissues from B-cell lymphoma patients was analyzed by immunohistochemical (IHC) double-staining. The mechanistic… More >

Yin-Lun Chang^1,2, Hao-Lun Luo¹, Jei-Ming Peng^3,*, Chang-Chun Hsiao^2,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.070837 - 23 March 2026

Abstract Background: Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy with high recurrence rates. Lymphovascular invasion (LVI) predicts a poor prognosis, yet its molecular drivers remain unclear. BOC cell adhesion-associated, oncogene-regulated (BOC, also known as Brother of CDO [Cell adhesion molecule-Related/Down-regulated by Oncogenes]), a hedgehog-related cell surface receptor, may serve as a biomarker for tumor progression and chemotherapy response. The study aimed to investigate the role of BOC in UTUC and its potential to predict LVI and chemotherapy response. Methods: Sequencing (RNA-seq) of 10 stage III UTUC, treatment-naïve, fresh tissue samples identified BOC as a… More >

Eva Donck^1,*, Sofie Verbeke², Pieter De Visschere³, Valérie Fonteyne⁴, Charles Van Praet¹, Kathia De Man⁵, Nicolaas Lumen¹

Canadian Journal of Urology, Vol.33, No.1, pp. 83-92, 2026, DOI:10.32604/cju.2025.068589 - 28 February 2026

Abstract Objectives: PSMA PET/CT (Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography) offers improved accuracy in detecting lymph node invasion (LNI) in prostate cancer (PC) patients, potentially reducing the need for extended pelvic lymph node dissection (ePLND). This study aims to evaluate a patient-tailored care pathway in which ePLND is performed only in patients with unfavorable intermediate- or high-risk PC who are deemed at risk for LNI based on PSMA PET/CT findings. Methods: In this interventional cohort study, 81 patients were managed according to the new care pathway. ePLND was omitted in cases of negative PSMA PET/CT… More >

Dorian Dikov¹, Maria Koleva^2,*, Kiril Simitchiev³, Anelia Bivolarska⁴, Albena Fakirova⁵, Victoria Sarafian^6,7

Canadian Journal of Urology, Vol.33, No.1, pp. 125-134, 2026, DOI:10.32604/cju.2025.068575 - 28 February 2026

Abstract Background: Chronic inflammation is closely associated with the most common and socially significant prostate conditions, including benign prostatic hyperplasia (BPH), prostate cancer (PCa), and prostatitis syndromes. NIH-category IV prostatitis (histologic prostatitis, HP) is defined as asymptomatic chronic inflammation of the prostate. The presence of lymphoid follicles, referred to as tertiary lymphoid structures (TLSs), along with benign lympho-epithelial lesions (BLELs), is among the key histological indicators of immune inflammation and can be assessed relatively easily. This study aimed to quantitatively assess TLSs and BLELs, as well as their relationship with the severity of HP. Methods: We… More >

Yuriy Mayasin^1,*, Maria Osinnikova², Daria Osadchaya¹, Victoria Dmitrienko¹, Anna Gorodilova¹, Chulpan Kharisova¹, Kristina Kitaeva¹, Valeria Solovyeva¹, Albert Rizvanov^1,3

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.073008 - 24 February 2026

Abstract Classical Hodgkin lymphoma (cHL) is characterized by rare Hodgkin/Reed-Sternberg (HRS) tumor cells that uniformly express cluster of differentiation (CD)30 molecules and orchestrate an immunosuppressive tumor microenvironment, making CD30 an attractive and selective therapeutic target. We summarize the biological rationale for CD30 as a therapeutic target and the preclinical and clinical evidence across major platforms: antibody-drug conjugates (brentuximab vedotin), monoclonal antibodies (including acimtamig and its combinations with Natural Killer cells), second- and third-generation chimeric antigen receptor (CAR)-T cells, and alternative modalities. Particular attention is given to standardized response assessment (IWG, Lugano, RECIL criteria), which enables appropriate… More >